CHRS NASDAQ
Coherus Oncology, Inc.
1W: +2.6%
1M: -18.3%
3M: -25.6%
YTD: -15.3%
1Y: -28.4%
3Y: -70.8%
5Y: -93.5%
$1.16
+0.00 (+0.00%)
Weekly Expected Move ±10.7%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
24 relationships24
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2022-01-13
Earliest Filing
2025-04-14
Latest Filing
partner: 10
acquirer: 6
target: 4
licensee: 2
investor: 1
customer: 1
Counterparties (Filed by CHRS)
24 relationshipsCompanies named in CHRS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Coduet Royalty Holdings, LLC | — | investor | Held Revenue Participation Rights in the UDENYCA franchise that were assumed by the acquirer. | 2025-04-14 | View |
| Hong Kong King-Friend Industrial Company Ltd. | — | acquirer | Acquired Coherus BioSciences' YUSIMRY franchise through an asset sale. | 2025-04-14 | View |
| Sandoz Inc. | — | acquirer | Acquired Coherus BioSciences' CIMERLI ophthalmology franchise via subsidiary Coherus Ophthalmology LLC. | 2025-04-14 | View |
| Intas Pharmaceuticals Ltd. | — | acquirer | Acquired Coherus BioSciences' UDENYCA franchise for $483.4 million in cash. | 2025-04-14 | View |
| Intas Pharmaceuticals Ltd. | — | target | Acquired UDENYCA franchise by Coherus BioSciences, Inc. | 2025-04-01 | View |
| Shanghai Junshi Biosciences Co., Ltd. | — | partner | Original collaborator for co-development and commercialization of toripalimab | 2024-07-02 | View |
| Apotex, Inc. | — | licensee | Granted exclusive license to commercialize toripalimab in Canada | 2024-07-02 | View |
| Surface Oncology, Inc. | — | target | Target of the Surface Merger acquired by Coherus BioSciences, Inc. | 2024-06-27 | View |
| Sandoz Inc. | — | acquirer | Acquired Coherus Ophthalmology LLC (CIMERLI franchise) in a pro forma transaction. | 2024-06-27 | View |
| Meitheal Pharmaceuticals, Inc. | — | partner | Identified as a subsidiary of Hong Kong King-Friend Industrial Company Ltd. | 2024-06-27 | View |
| Hong Kong King-Friend Industrial Company Ltd. | — | acquirer | Acquired YUSIMRY franchise assets from Coherus BioSciences, Inc. for $40.0 million. | 2024-06-27 | View |
| Sandoz Inc. | — | customer | Purchased Coherus Ophthalmology LLC and the CIMERLI franchise for $170 million plus inventory assets. | 2024-03-04 | View |
| Sandoz Inc. | — | partner | Counterparty to the Purchase and Sale Agreement | 2024-02-05 | View |
| Sandoz Inc. | — | acquirer | Acquired Coherus BioSciences' CIMERLI ophthalmology franchise for $170 million in cash plus inventory value. | 2024-01-22 | View |
| Hudson 333 Twin Dolphin Plaza, LLC | — | partner | Landlord for the office lease amendment extending the term through September 30, 2027. | 2023-10-27 | View |
| Cowen and Company, LLC | — | partner | Amended sales agreement to adjust ATM program offering price | 2023-09-12 | View |
| Computershare Trust Company, N.A. | — | partner | Rights agent for the contingent value right (CVR) agreement. | 2023-09-08 | View |
| Surface Oncology, Inc. | — | target | Target company acquired via merger agreement effective September 8, 2023. | 2023-09-08 | View |
| GlaxoSmithKline Intellectual Property (No. 4) Limited | — | partner | Licensee under the License Agreement dated December 16, 2020. | 2023-06-16 | View |
| Novartis Institute for Biomedical Research, Inc. | NVSEF | partner | Counterparty to the Novartis Agreement Collaboration Agreement dated January 9, 2016. | 2023-06-16 | View |
| Surface Oncology, Inc. | — | target | Target company in the merger agreement with Coherus BioSciences, Inc. | 2023-06-16 | View |
| Cowen and Company, LLC | — | partner | Amendment to sales agreement reducing ATM program offering price | 2023-05-15 | View |
| Innovent Biologics (Suzhou) Co., Ltd. | — | licensee | License Agreement terminated by Coherus BioSciences, Inc. | 2022-05-05 | View |
| Shanghai Junshi Biosciences, Co., Ltd | — | partner | Exclusive License and Commercialization Agreement for TIGIT program co-development and commercialization | 2022-01-13 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-28 | Other Events; Exhibits | View | |
| 2026-08-17 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-17 | Material Agreement; Termination of Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-06-15 | Accountant Change; Exhibits | View | |
| 2026-06-01 | Shareholder Vote | View | |
| 2026-03-09 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-17 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-04 | Other Events | View | |
| 2026-01-23 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-13 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-08 | Other Events | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-03 | Notice of Delisting or Transfer | View | |
| 2025-06-13 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-30 | Amendments to Articles of Incorporation or Bylaws; Regulation FD Disclosure; Financial Statements an | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-25 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR